blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4013390

EP4013390 - PHARMACEUTICAL COMPOSITIONS COMPRISING A COMBINATION OF OPIOID ANTAGONISTS [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  27.04.2024
Database last updated on 18.11.2024
FormerRequest for examination was made
Status updated on  20.05.2022
FormerThe international publication has been made
Status updated on  19.02.2021
Formerunknown
Status updated on  01.09.2020
Most recent event   Tooltip09.10.2024New entry: Additional fee for renewal fee: despatch of communication + time limit 
Applicant(s)For all designated states
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD
Hi Tech Park
Edmond J. Safra Campus
Givat Ram
9139002 Jerusalem / IL
[2022/25]
Inventor(s)01 / BARENHOLZ, Yechezkel
18 Nave Shaanan Street
9370719 Jerusalem / IL
02 / CERN, Ahuva
12/4 Nahal Naaman
7173561 Modiin / IL
 [2022/25]
Representative(s)HGF
HGF Limited
1 City Walk
Leeds LS11 9DX / GB
[2022/25]
Application number, filing date20760938.912.08.2020
[2022/25]
WO2020IL50884
Priority number, dateUS201962885569P12.08.2019         Original published format: US 201962885569 P
[2022/25]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021028916
Date:18.02.2021
Language:EN
[2021/07]
Type: A1 Application with search report 
No.:EP4013390
Date:22.06.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 18.02.2021 takes the place of the publication of the European patent application.
[2022/25]
Search report(s)International search report - published on:EP18.02.2021
ClassificationIPC:A61K9/127, A61K31/485, A61K31/5377, A61K9/06, A61K47/34, A61K9/00
[2022/25]
CPC:
A61K9/1271 (EP); A61K45/06 (EP,CN); A61K31/485 (EP,CN,US);
A61K31/5377 (EP,CN,US); A61K47/32 (CN); A61K47/36 (CN);
A61K47/38 (CN); A61K9/0019 (EP,CN); A61K9/06 (EP,CN);
A61K9/127 (EP,CN,US); A61P25/00 (CN) (-)
C-Set:
A61K31/485, A61K2300/00 (EP,CN);
A61K31/5377, A61K2300/00 (CN,EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/25]
TitleGerman:PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT EINER KOMBINATION VON OPIOID-ANTAGONISTEN[2022/25]
English:PHARMACEUTICAL COMPOSITIONS COMPRISING A COMBINATION OF OPIOID ANTAGONISTS[2022/25]
French:COMPOSITIONS PHARMACEUTIQUES COMPRENANT UNE COMBINAISON D'ANTAGONISTES OPIOÏDES[2022/25]
Entry into regional phase24.02.2022National basic fee paid 
24.02.2022Designation fee(s) paid 
24.02.2022Examination fee paid 
Examination procedure24.02.2022Amendment by applicant (claims and/or description)
24.02.2022Examination requested  [2022/25]
24.02.2022Date on which the examining division has become responsible
29.04.2024Despatch of a communication from the examining division (Time limit: M04)
13.09.2024Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
Fees paidRenewal fee
25.08.2022Renewal fee patent year 03
25.08.2023Renewal fee patent year 04
Penalty fee
Additional fee for renewal fee
31.08.202405   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[Y]EP0300806  (VESTAR INC [US]) [Y] 1-22 * claim 1 * * example 1 *;
 [Y]US2002065506  (GRUBER ANDRAS [US], et al) [Y] 1-22 * claims 1-16 * * example 1 *;
 [Y]WO02087482  (PURDUE PHARMA LP [US], et al) [Y] 1-22 * claims 9-12 * * page 9, line 13 - line 15 *;
 [Y]US2012270848  (MANNION JAMES C [US], et al) [Y] 5-7,12-14,20-22 * paragraph [0059] ** claims 16-20 *;
 [Y]US2016346205  (HEATH TIMOTHY D [US], et al) [Y] 1-22 * examples 3,15 *;
 [Y]US2019201344  (HAYWARD STEPHEN L [US], et al) [Y] 1-22 * claims 1-6 * * paragraph [0035] * * paragraph [0046] - paragraph [0047] *;
 [Y]  - "Sladky KK, Krugner-Higby L, Meek-Walker E, et al. Serum concentrations and analgesic effects of liposome-encapsulated and standard butorphanol tartrate in parrots. Am J Vet Res 67:775-781, 2006 ED - Guzman David Sanchez-Migallon", JOURNAL OF EXOTIC PET MEDICINE, W.B. SAUNDERS CO, PHILADELPHIA, PA, US, (20070101), vol. 16, no. 1, ISSN 1557-5063, page 62, XP022019821 [Y] 1-22 * the whole document *
by applicant   - YUEN KH et al., "Comparative bioavailability study of a generic naltrexone tablet preparation", Drug Dev Ind Pharm, (19990000), vol. 25, pages 353 - 356
    - CASSEL JA et al., "3 H]Alvimopan binding to the m opioid receptor: comparative binding kinetics of opioid antagonists", Eur J Pharmacol, (20050000), vol. 520, doi:10.1016/j.ejphar.2005.08.008, pages 29 - 36, XP005090445

DOI:   http://dx.doi.org/10.1016/j.ejphar.2005.08.008
    - CHAUDHARY AKHAN M FDHILLON S S et al., "A Review of Samidorphan: A Novel Opioid Antagonist", Cureus, (20190715), vol. 11, no. 7, page e5139
    - STEINMAN, N. Y.HAIM-ZADA, M.GOLDSTEIN, I. A.GOLDBERG, A. H.HABER, T.BERLIN, J. M.DOMB, A. J., "Effect of PLGA block molecular weight on gelling temperature of PLGA-PEG-PLGA thermoresponsive copolymers", J. Polym. Sci. Part A: Polym. Chem., (20190000), vol. 57, pages 35 - 39
    - GARBUZENKO O. et al., Langmuir, (20050000), vol. 21, pages 2560 - 2568
    - M. JAFARI-NODOUSHANJ. BARZINH. MOBEDI, "A stability-indicating HPLC method for simultaneous determination of morphine and naltrexone", J. Chromatogr. B Anal. Technol. Biomed. Life Sci., (20160000), vol. 1011, doi:10.1016/j.jchromb.2015.12.048, pages 163 - 170, XP029398562

DOI:   http://dx.doi.org/10.1016/j.jchromb.2015.12.048
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.